Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel R Denmeade

Showing results (1-10 of 155) with videos related to

Pageof 16
Sort By:
Clinical Advances in Hematology & Oncology : H&O|August 2, 2018
Bipolar androgen therapy in the treatment of prostate cancerSamuel R Denmeade
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2024
Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate CancerSamuel R Denmeade
The Annals of Pharmacotherapy|July 31, 2008
Left posterior fascicular block due to high-dose interleukin-2Anand Singla, Samuel R Denmeade
The Prostate|January 27, 2004
Development of prostate cancer treatment: the good newsSamuel R Denmeade, John T Isaacs
Cancer Research|June 19, 2021
Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?Laura A Sena, Samuel R Denmeade
The Prostate|July 8, 2010
Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancerSamuel R Denmeade, John T Isaacs
Cancer Biology & Therapy|January 22, 2005
The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancerSamuel R Denmeade, John T Isaacs
Nature Reviews. Cancer|June 5, 2002
A history of prostate cancer treatmentSamuel R Denmeade, John T Isaacs
Oncotarget|July 28, 2012
Engineering enzymatically activated "molecular grenades" for cancerSamuel R Denmeade, John T Isaacs
Molecular Cancer Therapeutics|December 25, 2014
Protease-activated pore-forming peptides for the treatment and imaging of prostate cancerAaron M LeBeau, Samuel R Denmeade
Pageof 16

Showing results (1-10 of 155) with videos related to

Sort By:
Pageof 16
Clinical Advances in Hematology & Oncology : H&O|August 2, 2018
Bipolar androgen therapy in the treatment of prostate cancerSamuel R Denmeade
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2024
Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate CancerSamuel R Denmeade
The Annals of Pharmacotherapy|July 31, 2008
Left posterior fascicular block due to high-dose interleukin-2Anand Singla, Samuel R Denmeade
The Prostate|January 27, 2004
Development of prostate cancer treatment: the good newsSamuel R Denmeade, John T Isaacs
Cancer Research|June 19, 2021
Fatty Acid Synthesis in Prostate Cancer: Vulnerability or Epiphenomenon?Laura A Sena, Samuel R Denmeade
The Prostate|July 8, 2010
Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancerSamuel R Denmeade, John T Isaacs
Cancer Biology & Therapy|January 22, 2005
The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancerSamuel R Denmeade, John T Isaacs
Nature Reviews. Cancer|June 5, 2002
A history of prostate cancer treatmentSamuel R Denmeade, John T Isaacs
Oncotarget|July 28, 2012
Engineering enzymatically activated "molecular grenades" for cancerSamuel R Denmeade, John T Isaacs
Molecular Cancer Therapeutics|December 25, 2014
Protease-activated pore-forming peptides for the treatment and imaging of prostate cancerAaron M LeBeau, Samuel R Denmeade
Pageof 16